Advanz Pharma’s Ocaliva Loses EU Conditional Marketing Authorization

 
• By Francesca Bruce
  
PBC
Advanz Pharma is considering its next steps after the CMA for Ocaliva is revoked
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Pathways & Standards